WO2010061208A2 - Traitement therapeutique 555 - Google Patents

Traitement therapeutique 555 Download PDF

Info

Publication number
WO2010061208A2
WO2010061208A2 PCT/GB2009/051471 GB2009051471W WO2010061208A2 WO 2010061208 A2 WO2010061208 A2 WO 2010061208A2 GB 2009051471 W GB2009051471 W GB 2009051471W WO 2010061208 A2 WO2010061208 A2 WO 2010061208A2
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
compound
combination
treatment
taxane
Prior art date
Application number
PCT/GB2009/051471
Other languages
English (en)
Other versions
WO2010061208A3 (fr
Inventor
Daniel Mark Hickinson
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Publication of WO2010061208A2 publication Critical patent/WO2010061208A2/fr
Publication of WO2010061208A3 publication Critical patent/WO2010061208A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une combinaison comprenant 4-(3-chloro-2-fluoroanilino)-7-méthoxy-6-{[l-(N- méthylcarbamoylméthyl)pipéridine-4-yl ]oxy}quinazoléine, ou un sel de celle-ci pharmaceutiquement acceptable, et un taxane.
PCT/GB2009/051471 2008-11-03 2009-11-02 Traitement therapeutique 555 WO2010061208A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11071008P 2008-11-03 2008-11-03
US61/110,710 2008-11-03

Publications (2)

Publication Number Publication Date
WO2010061208A2 true WO2010061208A2 (fr) 2010-06-03
WO2010061208A3 WO2010061208A3 (fr) 2010-11-04

Family

ID=41528555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/051471 WO2010061208A2 (fr) 2008-11-03 2009-11-02 Traitement therapeutique 555

Country Status (1)

Country Link
WO (1) WO2010061208A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014135876A1 (fr) 2013-03-06 2014-09-12 Astrazeneca Ab Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
WO2003039551A1 (fr) * 2001-11-08 2003-05-15 Astrazeneca Ab Therapie combinant l'utilisation de zd6474 et d'un taxane
WO2005028469A1 (fr) * 2003-09-19 2005-03-31 Astrazeneca Ab Derives de quinazoline
WO2009138781A1 (fr) * 2008-05-13 2009-11-19 Astrazeneca Ab Sel de fumarate de 4-(3-chloro-2-fluoroanilino)-7-méthoxy-6-{[1-(n-méthylcarbamoylméthyl)pipéridin-4-yl]oxy}quinazoline

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
WO2003039551A1 (fr) * 2001-11-08 2003-05-15 Astrazeneca Ab Therapie combinant l'utilisation de zd6474 et d'un taxane
US20050043395A1 (en) * 2001-11-08 2005-02-24 Astrazeneca Ab Combination therapy comprising zd6474 and a taxane
WO2005028469A1 (fr) * 2003-09-19 2005-03-31 Astrazeneca Ab Derives de quinazoline
WO2009138781A1 (fr) * 2008-05-13 2009-11-19 Astrazeneca Ab Sel de fumarate de 4-(3-chloro-2-fluoroanilino)-7-méthoxy-6-{[1-(n-méthylcarbamoylméthyl)pipéridin-4-yl]oxy}quinazoline

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CIARDIELLO F ET AL: "Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer" BRITISH JOURNAL OF CANCER, vol. 94, no. 11, June 2006 (2006-06), pages 1604-1609, XP002591605 ISSN: 0007-0920 *
DI LEO ANGELO ET AL: "Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer." JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 DEC 2008 LNKD- PUBMED:18955454, vol. 26, no. 34, 1 December 2008 (2008-12-01), pages 5544-5552, XP002591604 ISSN: 1527-7755 *
SHERI K DENNISON ET AL: "A phase II clinical trial of ZD1839 (Iressa(TM)) in combination with docetaxel as first-line treatment in patients with advanced breast cancer" INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO LNKD- DOI:10.1007/S10637-007-9055-6, vol. 25, no. 6, 12 June 2007 (2007-06-12), pages 545-551, XP019526143 ISSN: 1573-0646 *
TAKABATAKE DAISUKE ET AL: "Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCMADR, MDA-MB-231)" INTERNATIONAL JOURNAL OF CANCER, vol. 120, no. 1, January 2007 (2007-01), pages 181-188, XP002591603 ISSN: 0020-7136 *
XUE CHENGSEN ET AL: "ErbB3-dependent motility and intravasation in breast cancer metastasis." CANCER RESEARCH 1 FEB 2006 LNKD- PUBMED:16452197, vol. 66, no. 3, 1 February 2006 (2006-02-01), pages 1418-1426, XP002591606 ISSN: 0008-5472 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014135876A1 (fr) 2013-03-06 2014-09-12 Astrazeneca Ab Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
US9066979B2 (en) 2013-03-06 2015-06-30 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
US9375432B2 (en) 2013-03-06 2016-06-28 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
US9718806B2 (en) 2013-03-06 2017-08-01 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
EP3342770A1 (fr) 2013-03-06 2018-07-04 AstraZeneca AB Inhibiteurs de quinazoline pour activer des formes mutantes du récepteur du facteur de croissance épidermique

Also Published As

Publication number Publication date
WO2010061208A3 (fr) 2010-11-04

Similar Documents

Publication Publication Date Title
US20120252827A1 (en) Combination of therapy comprising zd6474 and a taxane
JP2022024025A (ja) 悪性腫瘍治療用製剤及び組成物
KR101475167B1 (ko) 복합 항암 요법
JP2010503717A (ja) Ｅｇｆｒ変異を有する腫瘍を治療するための方法
CN111643504A (zh) Akt抑制剂化合物和化疗剂的组合以及使用方法
CN111818925B (zh) Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途
AU2020391220A1 (en) Combination therapy involving diaryl macrocyclic compounds
US8404839B2 (en) Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A
WO2019057141A1 (fr) Utilisation de l'apatinib en association avec un inhibiteur de c-met dans la préparation d'un médicament pour le traitement de tumeurs
WO2014177915A1 (fr) Multi-thérapie anti-cancéreuse utilisant des dérivés de imidazo[4,5-c]quinoline
JP2016106092A (ja) 組合せ
JP5858989B2 (ja) 組合せ
TW202027750A (zh) 治療癌症之套組及其方法
WO2010061208A2 (fr) Traitement therapeutique 555
AU2019292184A1 (en) Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
CN112843059A (zh) 一种取代丁烯酰胺的应用
CN114787151B (zh) 喹唑啉衍生物或其盐、或其药物组合物的用途
WO2009138779A1 (fr) Combinaison comprenant de la 4-(3-chloro-2-fluoroanilino)-7-méthoxy-6-{[1-(n-méthylcarbamoylméthyl)pipéridin-4-yl]oxy}quinazoline
CN112533600B (zh) 用于治疗小细胞肺癌的喹啉衍生物
WO2024097848A1 (fr) Sels de malonate et de glycolate d'un inhibiteur d'egfr
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09748138

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09748138

Country of ref document: EP

Kind code of ref document: A2